MeiraGTx Holdings plc Finite-Lived Intangible Asset, Expected Amortization, Year One
MeiraGTx Holdings plc (MGTX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $281.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2025-03-13
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $281.00K.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $285.00K.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $272.00K.
- 2021-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $306.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2024-12-31 | $281.00K 10-K · filed 2025-03-13 |
| 2023-12-31 | $285.00K 10-K · filed 2024-03-15 |
| 2022-12-31 | $272.00K 10-K · filed 2023-03-14 |
| 2021-12-31 | $306.00K 10-K · filed 2022-03-10 |
| 2020-12-31 | $306.36K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |